Poniard Pharmaceuticals Stock Fundamentals
| PARDDelisted Stock | USD 0.01 0.00 0.00% |
Poniard Pharmaceuticals fundamentals help investors to digest information that contributes to Poniard Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Poniard Pink Sheet. The fundamental analysis module provides a way to measure Poniard Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Poniard Pharmaceuticals pink sheet.
Poniard |
Poniard Pharmaceuticals Company Return On Equity Analysis
Poniard Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Poniard Pharmaceuticals Return On Equity | -2.1 |
Most of Poniard Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Poniard Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Poniard Pharmaceuticals has a Return On Equity of -2.1037. This is 91.22% lower than that of the Biotechnology sector and 94.23% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Poniard Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Poniard Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Poniard Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Poniard Pharmaceuticals competition to find correlations between indicators driving Poniard Pharmaceuticals's intrinsic value. More Info.Poniard Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Poniard Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Poniard Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Poniard Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Poniard Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Poniard Pharmaceuticals by comparing valuation metrics of similar companies.Poniard Pharmaceuticals is currently under evaluation in return on equity category among its peers.
Poniard Fundamentals
| Return On Equity | -2.1 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 434.76 K | ||||
| Shares Outstanding | 1.5 M | ||||
| Number Of Shares Shorted | 47.72 K | ||||
| Price To Earning | (0.01) X | ||||
| Price To Book | 0.1 X | ||||
| EBITDA | (13.04 M) | ||||
| Net Income | (30.05 M) | ||||
| Cash And Equivalents | 1.98 M | ||||
| Cash Per Share | 1.32 X | ||||
| Total Debt | 1.57 M | ||||
| Debt To Equity | 0.53 % | ||||
| Current Ratio | 0.76 X | ||||
| Book Value Per Share | 2.08 X | ||||
| Cash Flow From Operations | (24.28 M) | ||||
| Short Ratio | 2.56 X | ||||
| Earnings Per Share | (3.79) X | ||||
| Target Price | 1.0 | ||||
| Beta | 0.9 | ||||
| Market Capitalization | 29 | ||||
| Total Asset | 11.64 M | ||||
| Retained Earnings | (438.94 M) | ||||
| Working Capital | 3.6 M | ||||
| Current Asset | 5.22 M | ||||
| Current Liabilities | 1.62 M | ||||
| Z Score | -55.1 | ||||
| Net Asset | 11.64 M |
About Poniard Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Poniard Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Poniard Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Poniard Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington. PONIARD PHARMACEUT operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs 7 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Poniard Pink Sheet
If you are still planning to invest in Poniard Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Poniard Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |